Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Inhibition of the BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma. However, colon cancer patients harbouring the same BRAF(V600E) oncogenic lesion have poor prognosis and show only a very limited response to this drug. To investigate the cause of the limited therapeutic effect of PLX4032 in BRAF(V600E) mutant colon tumours, here we performed an RNA-interference-based genetic screen in human cells to search for kinases whose knockdown synergizes with BRAF(V600E) inhibition. We report that blockade of the epidermal growth factor receptor (EGFR) shows strong synergy with BRAF(V600E) inhibition. We find in multiple BRAF(V600E) mutant colon cancers that inhibition of EGFR by the antibody drug cetuximab or the small-molecule drugs gefitinib or erlotinib is strongly synergistic with BRAF(V600E) inhibition, both in vitro and in vivo. Mechanistically, we find that BRAF(V600E) inhibition causes a rapid feedback activation of EGFR, which supports continued proliferation in the presence of BRAF(V600E) inhibition. Melanoma cells express low levels of EGFR and are therefore not subject to this feedback activation. Consistent with this, we find that ectopic expression of EGFR in melanoma cells is sufficient to cause resistance to PLX4032. Our data suggest that BRAF(V600E) mutant colon cancers (approximately 8-10% of all colon cancers), for which there are currently no targeted treatment options available, might benefit from combination therapy consisting of BRAF and EGFR inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF inhibition in BRAFV600 mutant cancers leads to loss of negative feedback signals regulated by the MAPK pathway, leading to receptor tyrosine kinase (RTK)-mediated reactivation of MAPK signaling through wild type RAS and RAF, particularly in specific tumor types, such as colorectal cancer (9–12).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, RTK-driven feedback reactivation of RAS-MAPK signaling has been identified as a key driver of resistance in BRAFV600E cancers treated with BRAF inhibitors (colorectal cancer in particular) and in KRAS-mutant cancers treated with MEK inhibitors (11,12,32).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This finding is consistent with prior studies identifying HER family and FGFR signaling as key mediators of adaptive feedback to RAS-MAPK pathway inhibitors (10–14,21,22) and recent functional genomic screens(40).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, adaptive feedback resistance has been a key limitation in prior clinical efforts to target the RAS-MAPK pathway.”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prevalence of BRAF V600E mutations in mCRC is 8–10%, and they occur only in KRAS-WT mCRC [159,160].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [159]
Experimental — accuracy not yet measured
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“shRNA inserts were retrieved from 8mg genomic DNA by PCR amplification (PCR1 and PCR2, see below for primer information) using the following conditions: (1) 98 uC, 30 s; (2) 98 uC, 10 s; (3) 60 uC, 20 s; (4) 72 uC, 1 min; (5) to step (2), 15 cycles; (6) 72 uC, 5 min; (7) 4 uC.”
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“Figure 1e shows that inhibition of EGFR does not significantly affect proliferation of EGFR in WiDr cells, consistent with the clinical observations that KRAS or BRAF mutant CRC cells do not respond to EGFR-targeted monoclonal antibodie”
ResultEpidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,707
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 1×
“shRNA inserts were retrieved from 8mg genomic DNA by PCR amplification (PCR1 and PCR2, see below for primer information) using the following conditions: (1) 98 uC, 30 s; (2) 98 uC, 10 s; (3) 60 uC, 20 s; (4) 72 uC, 1 min; (5) to step (2), 15 cycles; (6) 72 uC, 5 min; (7) 4 uC.”
Self-citationThe Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,158
Cited by
Items 401–500 of 1,012
Differential Reprogramming of Isogenic Colorectal Cancer Cells by Distinct Activating KRAS Mutations
Hammond, D. E., Mageean, C. J., Rusilowicz, E. V., Wickenden, J. A., Clague, M. J., & Prior, I. A. (2015) · Journal of Proteome Research · doi:10.1021/pr501191a · Cited by 81
Adackapara, C., Sholl, L. M., Barletta, J. A., & Hornick, J. L. (2013) · Histopathology · doi:10.1111/his.12154 · Cited by 86
Garbe, C., & Eigentler, T. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_6 · Cited by 88
Synthetic lethal strategies for the development of cancer therapeutics
Ngoi, N. Y. L., Gallo, D., Torrado, C., Nardo, M., Durocher, D., & Yap, T. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00966-z · Cited by 88
Ali, S. M., Sanford, E. M., Klempner, S. J., Rubinson, D. A., Wang, K., Palma, N. A., Chmielecki, J., Yelensky, R., Palmer, G. A., Morosini, D., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0378 · Cited by 83
RasGRP1 opposes proliferative EGFR–SOS1–Ras signals and restricts intestinal epithelial cell growth
Depeille, P., Henricks, L. M., van de Ven, R. A. H., Lemmens, E., Wang, C.-Y., Matli, M., Werb, Z., Haigis, K. M., Donner, D., Warren, R., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3175 · Cited by 80
Lim, S., Khoo, R., Juang, Y.-C., Gopal, P., Zhang, H., Yeo, C., Peh, K. M., Teo, J., Ng, S., Henry, B., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01337 · Cited by 80
Coffee, E. M., Faber, A. C., Roper, J., Sinnamon, M. J., Goel, G., Keung, L., Wang, W. V., Vecchione, L., de Vriendt, V., Weinstein, B. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2556 · Cited by 79
Systemic treatment for metastatic colorectal cancer in the era of precision medicine
Sandhu, J. S., Lavingia, V. K., & Fakih, M. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25421 · Cited by 86
Drilon, A. E. D. C., Sharma, M. R., Johnson, M. L., Yap, T. A., Gadgeel, S. M., Nepert, D. L., Feng, G., Reddy, M. B., Harney, A. S., Elsayed, M., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0361 · Cited by 82
Hirshfield, K. M., Tolkunov, D., Zhong, J., Ali, S. M., Stein, M. N., Murphy, S., Vig, H. S., Vázquez, A., Glod, J. W., Moss, R. A., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0049 · Cited by 88
B-Raf Inhibition in the Clinic: Present and Future
Fiskus, W. C., & Mitsiades, N. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-090514-030732 · Cited by 85
Fouassier, L., Marzioni, M., Afonso, M. B., Dooley, S., Gaston, K., Giannelli, G., Rodrigues, C. M. P., Lozano, E., Mancarella, S., Segatto, O., et al. (2019) · Liver International · doi:10.1111/liv.14102 · Cited by 83
Nunno, V. D., Gatto, L., Tosoni, A., Bartolini, S., & Franceschi, E. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1067252 · Cited by 88
Critical parameters in targeted drug development: the pharmacological audit trail
Banerji, U., & Workman, P. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.06.001 · Cited by 75
The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas
Nussinov, R., Muratcioglu, S., Tsai, C.-J., Jang, H., Gursoy, A., & Keskin, O. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0165 · Cited by 78
Kim, J.-Y., Welsh, E. A., Fang, B., Bai, Y., Kinose, F., Eschrich, S. A., Koomen, J. M., & Haura, E. B. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0506 · Cited by 76
Lin, X., Hu, L., Gu, J., Wang, R., Li, L., Tang, J. P., Zhang, B., Yan, X., Zhu, Y., Hu, C., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.12.033 · Cited by 80
Hazar-Rethinam, M., Kleyman, M., Han, G. C., Liu, D., Ahronian, L. G., Shahzade, H. A., Chen, L., Parikh, A. R., Allen, J. N., Clark, J. W., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1227 · Cited by 75
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer
Taieb, J., Jung, A., Sartore-Bianchi, A., Peeters, M., Seligmann, J., Zaanan, A., Burdon, P., Montagut, C., & Laurent-Puig, P. (2019) · Drugs · doi:10.1007/s40265-019-01165-2 · Cited by 76
BRAF Mutated Colorectal Cancer: New Treatment Approaches
Molina‐Cerrillo, J., Román, M. S., Pozas, J., Alonso‐Gordoa, T., Pozas, M., Conde, E., Cancio-Suárez, M. R., Grande, E., García‐Bermejo, L., & Carrato, A. (2020) · Cancers · doi:10.3390/cancers12061571 · Cited by 89
Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF
Thiel, A., & Ristimäki, A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00281 · Cited by 70
MEK genomics in development and disease
Bromberg-White, J. L., Andersen, N. J., & Duesbery, N. S. (2012) · Briefings in Functional Genomics · doi:10.1093/bfgp/els022 · Cited by 78
Cancer’s Achilles’ Heel: Apoptosis and Necroptosis to the Rescue
Dasgupta, A., Nomura, M., Shuck, R. L., & Yustein, J. T. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms18010023 · Cited by 87
Wu, C., Sim, H., Huang, Y.-H., Liu, Y., Hsiao, S.-H., Cheng, H.-W., Li, Y., Ambudkar, S. V., & Hsu, S. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.003 · Cited by 81
von Euw, E., Atefi, M. S., Attar, N., Chu, C., Zachariah, S., Burgess, B. L., Mok, S., Ng, C., Wong, D. J. L., Chmielowski, B., et al. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-22 · Cited by 81
The combinatorial complexity of cancer precision medicine
Klauschen, F., Andreeff, M., Keilholz, U., Dietel, M., & Stenzinger, A. (2014) · Oncoscience · doi:10.18632/oncoscience.66 · Cited by 80
Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease
Sherman, D. J., & Li, J. (2020) · Molecules · doi:10.3390/molecules25030671 · Cited by 84
Kim, H., Frederick, D. T., Levesque, M. P., Cooper, Z. A., Feng, Y., Krepler, C., Brill, L. M., Samuels, Y., Hayward, N. K., Perlina, A., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.049 · Cited by 79
Genomics of Hairy Cell Leukemia
Tiacci, E., Pettirossi, V., Schiavoni, G., & Falini, B. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.1556 · Cited by 83
Combès, E., Andrade, A. F., Tosi, D., Michaud, H., Coquel, F., Garambois, V., Désigaud, D., Jarlier, M., Coquelle, A., Pasero, P., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2807 · Cited by 78
Self-citationExploring the best treatment options for BRAF-mutant metastatic colon cancer
Taieb, J., Lapeyre-Prost, A., Laurent Puig, P., & Zaanan, A. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0526-2 · Cited by 74
Therapeutics Targeting Mutant KRAS
Thein, K. Z., Biter, A. B., & Hong, D. S. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-033145 · Cited by 72
Response and Resistance to RAS Inhibition in Cancer
Ebright, R. Y., Dilly, J., Shaw, A. T., & Aguirre, A. J. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0349 · Cited by 83
Feedback regulation in cell signalling: Lessons for cancer therapeutics
Nguyen, L. K., & Kholodenko, B. Ν. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.09.024 · Cited by 83
Next-Generation Sequencing to Guide Clinical Trials
Siu, L. L., Conley, B. A., Boerner, S. A., & LoRusso, P. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3215 · Cited by 82
Multiplexed Fluorescence Imaging of ERK and Akt Activities and Cell-cycle Progression
Maryu, G., Matsuda, M., & Aoki, K. (2016) · Cell Structure and Function · doi:10.1247/csf.16007 · Cited by 81
Huang, L., Jiang, Y., & Chen, Y. (2017) · Scientific Reports · doi:10.1038/srep40752 · Cited by 84
Whittaker, S. R., Cowley, G. S., Wagner, S., Luo, F., Root, D. E., & Garraway, L. A. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0136-t · Cited by 75
Translating Genomics for Precision Cancer Medicine
Roychowdhury, S., & Chinnaiyan, A. M. (2014) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090413-025552 · Cited by 84
Wang, J., Pollard, K., Allen, A. N., Tomar, T., Pijnenburg, D., Yao, Z., Rodriguez, F. J., & Pratilas, C. A. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1365 · Cited by 69
Won, J., Yang, H. W., Shin, S., Lee, J., Heo, W. D., & Cho, K. (2012) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjs021 · Cited by 80
The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma
Ahn, A., Chatterjee, A., & Eccles, M. R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0535 · Cited by 81
Lazzari, L., Corti, G., Picco, G., Isella, C., Montone, M., Arcella, P., Durinikova, E., Zanella, E. R., Novara, L., Barbosa, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3440 · Cited by 74
Self-citationChen, S.-H., Gong, X., Zhang, Y., Horn, R. D. V., Yin, T., Huber, L., Burke, T., Manro, J. R., Iversen, P. W., Wu, W., et al. (2017) · Oncogene · doi:10.1038/onc.2017.384 · Cited by 77
Westphalen, C. B., Martins-Branco, D. A., Beal, J. R., Cardone, C., Coleman, N., Schram, A. M., Halabi, S., Michiels, S., Yap, C., André, F., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.07.730 · Cited by 80
Kloth, M., Ruesseler, V., Engel, C., Koenig, K., Peifer, M., Mariotti, E., Kuenstlinger, H., Florin, A., Rommerscheidt-Fuss, U., Koitzsch, U., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-309026 · Cited by 73
The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer
Mauri, G., Bonazzina, E., Amatu, A., Tosi, F., Bencardino, K., Gori, V., Massihnia, D., Cipani, T., Spina, F., Ghezzi, S., et al. (2021) · Cancers · doi:10.3390/cancers13010137 · Cited by 73
“Subsequently, preclinical studies allowed to shed light on mechanisms of primary resistance to BRAF blockade in this tumor: differently from melanoma, in CRC anti-BRAF monotherapy induces a feedback activation of EGFR that re-activate the oncogenic pathway providing pharmacological escape [27] (Figure 1).”
BackgroundAdaptive stress signaling in targeted cancer therapy resistance
Pazarentzos, E., & Bivona, T. G. (2015) · Oncogene · doi:10.1038/onc.2015.26 · Cited by 69
Schoeberl, B., Kudla, A. J., Masson, K., Kalra, A. V., Curley, M., Finn, G. J., Pace, E. A., Harms, B. D., Kim, J., Kearns, J. D., et al. (2017) · npj Systems Biology and Applications · doi:10.1038/npjsba.2016.34 · Cited by 75
BLAST: Bayesian Latent Subgroup Design for Basket Trials Accounting for Patient Heterogeneity
Chu, Y., & Yuan, Y. (2018) · Journal of the Royal Statistical Society Series C (Applied Statistics) · doi:10.1111/rssc.12255 · Cited by 73
Juan, J., Muraguchi, T., Iezza, G., Sears, R. C., & McMahon, M. (2014) · Genes & Development · doi:10.1101/gad.233627.113 · Cited by 75
Adamopoulos, C., Ahmed, T. A., Tucker, M. R., Ung, P. M. U., Xiao, M., Karoulia, Z., Amabile, A., Wu, X., Aaronson, S. A., Ang, C., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1351 · Cited by 67
The Evolving Treatment Landscape in BRAF-V600E–Mutated Metastatic Colorectal Cancer
Tabernero, J., Ros, J., & Élez, E. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349561 · Cited by 59
Russo, M., Pompei, S., Sogari, A., Corigliano, M., Crisafulli, G., Puliafito, A., Lamba, S., Erriquez, J., Bertotti, A., Gherardi, M., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01105-z · Cited by 78
Self-citationRocca, A., Braga, L., Volpe, M. C., Maiocchi, S., & Generali, D. (2022) · Cancers · doi:10.3390/cancers14215306 · Cited by 79
Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma
Carlino, M. S., Long, G. V., Kefford, R. F., & Rizos, H. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.021 · Cited by 76
Modugno, F., & Edwards, R. P. (2012) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31826bd1f2 · Cited by 78
AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma
Hu, W., Jin, L., Jiang, C. C., Long, G. V., Scolyer, R. A., Wu, Q., Zhang, X. D., Mei, Y., & Wu, M. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.441 · Cited by 69
Oncogene Mimicry as a Mechanism of Primary Resistance to BRAF Inhibitors
Sos, M. L., Levin, R. S., Gordan, J. D., Oses-Prieto, J. A., Webber, J. T., Salt, M., Hann, B., Burlingame, A. L., McCormick, F., Bandyopadhyay, S., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.010 · Cited by 73
Novel Targets for the Treatment of Ameloblastoma
Heikinheimo, K., Kurppa, K. J., & Elenius, K. (2014) · Journal of Dental Research · doi:10.1177/0022034514560373 · Cited by 79
Vakana, E., Pratt, S., Blosser, W., Dowless, M., Simpson, N., Yuan, X.-J., Jaken, S., Manro, J., Stephens, J., Zhang, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14002 · Cited by 70
Potential of the Synthetic Lethality Principle
Nijman, S. M. B., & Friend, S. H. (2013) · Science · doi:10.1126/science.1244669 · Cited by 72
Matos, A. I., Carreira, B., Peres, C., Moura, L. I. F., Conniot, J., Fourniols, T., Scomparin, A., Martínez-Barriocanal, Á., Arango, D., Conde, J. P., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.017 · Cited by 68
The Therapeutic Potential of MAPK/ERK Inhibitors in the Treatment of Colorectal Cancer
Pashirzad, M., Khorasanian, R., Fard, M. M., Arjmand, M., Langari, H., Khazaei, M., Soleimanpour, S., Rezayi, M., Ferns, G. A., Hassanian, S. M., et al. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666211103113339 · Cited by 74
Base editing screens define the genetic landscape of cancer drug resistance mechanisms
Coelho, M. A., Strauß, M. E., Watterson, A., Cooper, S., Bhosle, S. G., Illuzzi, G., Karakoç, E., Dinçer, C., Vieira, S. F., Sharma, M., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01948-8 · Cited by 75
Carson, R., Çeltikçi, B., Fenning, C., Javadi, A., Crawford, N., Pérez–Carbonell, L., Lawler, M., Longley, D. B., Johnston, P. G., & Schaeybroeck, S. V. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2701 · Cited by 77
Hammerlindl, H., & Schaider, H. (2017) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-017-0435-1 · Cited by 75
Sclafani, F., Gullo, G., Sheahan, K. D., & Crown, J. P. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.11.003 · Cited by 76
Role of targeted agents in metastatic colorectal cancer
Prenen, H., Vecchione, L., & Cutsem, E. V. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0281-x · Cited by 79
BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity
Cabanillas, M. E., Patel, A. P., Danysh, B. P., Dadu, R., Kopetz, S., & Falchook, G. S. (2014) · Hormones and Cancer · doi:10.1007/s12672-014-0207-9 · Cited by 73
The complexities and versatility of the RAS-to-ERK signalling system in normal and cancer cells
Fey, D., Matallanas, D., Rauch, J., Rukhlenko, O. S., & Kholodenko, B. N. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.06.011 · Cited by 61
BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
Ros, J., Baraibar, I., Sardo, E., Mulet-Margalef, N., Salvà, F., Argilés, G., Martini, G., Ciardiello, D., Cuadra‐Urteaga, J. L., Tabernero, J. M., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835921992974 · Cited by 76
Ros, J., Balconi, F., Baraibar, I., Gonzalez, N. S., Salvà, F., Tabernero, J. M., & Élez, E. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1112276 · Cited by 74
Gonzalez, N. S., Salvà, F., Ros, J., Baraibar, I., Rodríguez-Castells, M., García, A., Alcaráz, A., Vega, S., Bueno, S., Tabernero, J. M., et al. (2023) · Cancers · doi:10.3390/cancers15164020 · Cited by 80
Methods of overcoming treatment resistance in colorectal cancer
Temraz, S. N., Mukherji, D., Alameddine, R. S., & Shamseddine, A. I. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.08.015 · Cited by 75
Enhancing the anti-colon cancer activity of quercetin by self-assembled micelles
Gao, X., Huang, N., Shi, H., Ren, L., Xu, G., Gou, H., & Gong, D. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s75550 · Cited by 92
Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies
Meador, C. B., Micheel, C. M., Levy, M. A., Lovly, C. M., Horn, L., Warner, J. L., Johnson, D. B., Zhao, Z., Anderson, I. A., Sosman, J. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1591 · Cited by 66
Molecular diagnostics and personalized medicine in oncology: Challenges and opportunities
Normanno, N., Rachiglio, A. M., Roma, C., Fenizia, F., Esposito, C., Pasquale, R., Porta, M. L. L., Iannaccone, A., Micheli, F., Santangelo, M. L., et al. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24401 · Cited by 74
Goulielmaki, M., Koustas, E., Moysidou, E., Vlassi, M., Sasazuki, T., Shirasawa, S., Zografos, G., Oikonomou, E., & Pintzas, A. (2016) · Oncotarget · doi:10.18632/oncotarget.6942 · Cited by 66
Ros, J., Matito, J., Villacampa, G. J., Comas, R., García, A., Martini, G., Baraibar, I., Gonzalez, N. S., Salvà, F., Martín, Á., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.02.016 · Cited by 72
de Cuba, E. M. V., Kwakman, R., van Egmond, M., Bosch, L. J. W., Bonjer, H. J., Meijer, G. A., & Velde, E. A. T. (2012) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-012-1287-y · Cited by 69
Chen, J., Guo, F., Shi, X., Zhang, L., Zhang, A., Jin, H., & He, Y. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-802 · Cited by 63
Mutational profiling of kinases in glioblastoma
Bleeker, F. E., Lamba, S., Zanon, C., Molenaar, R. J., Hulsebos, T. J. M., Troost, D., van Tilborg, A. A., Vandertop, W. P., Leenstra, S., Noorden, C. J. F. V., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-718 · Cited by 76
Self-citationIn Vitro and In Vivo Models for Analysis of Resistance to Anticancer Molecular Therapies
Rosa, R., Monteleone, F., Zambrano, N., & Bianco, R. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113209990226 · Cited by 76
Rethinking cancer: current challenges and opportunities in cancer research
Cagan, R. L., & Meyer, P. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.030007 · Cited by 67
Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer
Henry, J. T., Coker, O., Chowdhury, S., Shen, J. P., Morris, V. K., Dasari, A., Raghav, K., Nusrat, M., Kee, B., Parseghian, C., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00256 · Cited by 66
JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors
Gao, S. P., Chang, Q., Mao, N., Daly, L., VOGEL, R. M., Chan, T., Liu, S. H., Bournazou, E., Schori, E., Zhang, H., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aac8460 · Cited by 69
Cancer of Unknown Primary: Challenges and Progress in Clinical Management
Laprovitera, N., Riefolo, M., Ambrosini, E., Klec, C., Pichler, M., & Ferracin, M. (2021) · Cancers · doi:10.3390/cancers13030451 · Cited by 78
Tabernero, J., Van Cutsem, E., Garralda, E., Tai, D., De Braud, F., Geva, R., van Bussel, M. T. J., Fiorella Dotti, K., Elez, E., de Miguel, M. J., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad007 · Cited by 59
Joseph, R. W., Swaika, A., & Crozier, J. A. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s31143 · Cited by 80
Mechanisms of resistance to BCR-ABL and other kinase inhibitors
Lamontanara, A. J., Akçok, E. B. G., Kuzyk, O., & Hantschel, O. D. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2012.12.009 · Cited by 71
Beckman, R., Antonijevic, Z., Kalamegham, R., & Chen, C. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.446 · Cited by 70
Bomane, A., Gonçalvès, A., & Ballester, P. J. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01041 · Cited by 66
BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies
van Brummelen, E. M. J., de Boer, A., Beijnen, J. H., & Schellens, J. H. M. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0031 · Cited by 68
Altman, A. D., Nelson, G. S., Ghatage, P., McIntyre, J. B., Capper, D., Chu, P., Nation, J. G., Karnezis, A. N., Han, G., Kalloger, S. E., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.55 · Cited by 71
Discrete cytosolic macromolecular BRAF complexes exhibit distinct activities and composition
Diedrich, B., Rigbolt, K. T. G., Röring, M., Herr, R., Kaeser-Pebernard, S., Gretzmeier, C., Murphy, R. F., Brummer, T., & Dengjel, J. (2017) · The EMBO Journal · doi:10.15252/embj.201694732 · Cited by 68
BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
Cohen, R., Cervera, P., Svrcek, M., Pellat, A., Dreyer, C., de Gramont, A., & André, T. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0453-5 · Cited by 66
From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development
Lieu, C. H., Tan, A.-C., Leong, S., Diamond, J. R., & Eckhardt, S. G. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt209 · Cited by 61
Roth, B. J., Krilov, L., Adams, S., Aghajanian, C. A., Bach, P. B., Braiteh, F., Brose, M. S., Ellis, L. M., Erba, H. P., George, D. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.1938 · Cited by 71
Metadata
- Authors
- Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R.
- Affiliations
- The Netherlands Cancer Institute (NL)
- University of Turin (IT)
- IFOM (IT)
- Corresponding author
- Bernards, René
- ORCID
- Venue
- Nature
- Published
- 2012-01-26
- Volume
- 483
- Issue
- 7387
- Pages
- 100-103
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2014881369
- Semantic Scholar
- 10564d8dc4a3ddb05a84b5a3ca8b7b622c5c17ea
- Cited by
- 2,051
- References
- 22
- Citations by year
- 2026: 75 · 2025: 81 · 2024: 106 · 2023: 145 · 2022: 126 · 2021: 168 · 2020: 145 · 2019: 117 · 2018: 139 · 2017: 129 · 2016: 149 · 2015: 215 · 2014: 188 · 2013: 172 · 2012: 91
- FWCI
- 105.49
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- European Commission (259015)
- Ministero della Salute
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- KWF Kankerbestrijding
- Associazione Italiana per la Ricerca sul Cancro (5 x mille)
- Regione Piemonte
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- BRAF V600E mutation, colon cancer, EGFR, vemurafenib, drug resistance, feedback activation, cetuximab, gefitinib, erlotinib, combination therapy, RNAi screen, melanoma, targeted therapy
- MeSH terms
- Cetuximab, Erlotinib Hydrochloride, Gefitinib, Vemurafenib, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Drug Synergism, Enzyme Activation, Female, Humans, Indoles, Melanoma, Quinazolines, Sulfonamides, Colorectal Neoplasms, Apoptosis, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Feedback, Physiological, RNA Interference, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice, HEK293 Cells, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.